

Highly Efficient Synthesis of 1,4-Disubstituted 1,2,3-Triazole Derivatives under Ultrasonic Irradiation, Evaluation of Vasorelaxant Activities

Sakineh Ebrahimpourmoghaddam¹;PhD^{id}, Maryam Motevasel²;PhD, Saghar Mowlazadeh Haghighi¹;PhD, Azar Purkhosrow³;MSc, Hashem Sharghi¹;PhD, Ali Khalafinezhad¹;PhD, Elahe Sattarinezhad^{3*};PhD^{id}

¹Department of Chemistry, Shiraz University, Shiraz, Iran.

²Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

³Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

1,4-Disubstituted 1,2,3-Triazole derivatives are exciting pharmacophores with a wide range of biological activities, including anticancer, antituberculosis, antifungal, antibacterial, and anti-HIV. Due to their diverse uses, many efforts have been made to synthesize these valuable medicinal scaffolds. Unfortunately, most of them have difficult and time-consuming procedures, low yields of the products, or environmentally toxic residues, therefore, it is necessary to develop easy methods with high efficiency and without harmful by-products. In the first part of this study, differently decorated 1,4-disubstituted 1,2,3-triazole derivatives were synthesized through a one-pot, two-step procedure from epoxides, alkynes and sodium azide in the presence of Cu₂O in water under ultrasonic irradiation with high efficiency and without any toxic residues. In the second part of this research, the vasorelaxant activity of these triazole derivatives was studied in isolated rat thoracic aorta. Based on the results, three compounds have potent vasorelaxant activity and can be considered in future evaluations for the development of new antihypertensive drugs.

Keywords: Triazole, Ultrasonic irradiation, Vasorelaxant

Please cite this article as: Ebrahimpourmoghaddam S, Motevasel M, Mowlazadeh Haghighi S, Purkhosrow A, Sharghi H, Khalafinezhad A, Sattarinezhad E*. Highly Efficient Synthesis of 1,4-Disubstituted 1,2,3-Triazole Derivatives under Ultrasonic Irradiation, Evaluation of Vasorelaxant Activity. Trends in Pharmaceutical Sciences. 2024;10(1):67-76. doi: 10.30476/TIPS.2024.101918.1228

1. Introduction

1,4-Disubstituted 1,2,3-triazoles are attractive pharmacophores with a wide range of biological activities such as anticancer (1, 2), antituberculosis (3), antifungal (4), antimicrobial (5, 6), antiviral (7), analgesic (8) and anti-HIV (9). Furthermore, they have many applications in industry as dyestuffs, corrosion inhibitors, light stabilizers, optical brighteners and fluorescent whiteners (10). Due to their amazing properties and extensive uses, numerous methods have been developed to synthesize these valuable pharmaceutical scaffolds (11).

The traditional method for the synthesis of 1,2,3-triazoles is 1,3-dipolar cycloaddition reaction between alkynes and azide derivatives. This method requires multi-step procedures and high temperature and besides, leads to the production of a mixture of 1,4- and 1,5-disubstituted triazoles (12). A widely used copper-catalyzed variant of this reaction named “Huisgen reaction” makes it possible to conduct this reaction even at room temperature while using water as the green solvent (13). The reaction proceeds in the presence of a copper (I) catalyst to produce 1,4-disubstituted 1,2,3-triazoles exclusively (14). Copper (I) catalysis confers regioselectivity and enables us to use a wide variety of substrates. Despite all the advantage, Copper (I) is thermodynamically unstable and easily oxidates to copper (II) species and/or

Corresponding Author: Elahe Sattarinezhad, Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Email: elahasat@yahoo.com

disproportionation to copper (0) and copper (II) species (15). This unfavorable property of copper (I) generally slows down the reaction rate and usually requires the use of ligands which in turn may lead to the formation of harmful by-products (16). Accordingly, it is necessary to use a method to accelerate the reaction without leaving undesirable residues.

Ultrasonic chemistry has received an increasing attention for the synthesis of organic materials. It can make numerous organic reactions proceed in shorter time and milder conditions (17). Moreover, this approach leads to the production of pure products with high yields using simple and environmentally friendly methods (18). However, there are few reports on ultrasound-assisted 1,3-dipolar cycloaddition reactions. Therefore, considering the advantages of the ultrasonic method and with special attention to the importance of green chemistry, we designed a one-pot, two-step, efficient, regioselective and safe synthetic procedure to synthesize different decorated 1,4-disubstituted 1,2,3-triazole derivatives from epoxides, sodium azide, and alkynes in water, catalyzed by Cu_2O under ultrasonic irradiation at room temperature.

The vasorelaxant activities of various types of triazole derivatives have been reported by some authors. Biagi *et al.* designed and synthesized a series of 1,5-diphenylsubstituted 1,2,3-triazoles and reported their vasorelaxant effects (19). Baragatti *et al.* produced a series of 5-substituted-triazolyl-benzimidazolones and triazolyl-benzotriazoles as well as 1,5-Diarylsubstituted 1,2,3-triazoles and found them to be potent vasorelaxants (20).

In the second part of this research, we evaluated the cuted 1,2,3-triazole derivatives in isolated rat thoracic aorta.

2. Material and methods

2.1. Materials

2.1.1. Chemicals and equipments

All chemicals were of analytical grade and were purchased from Fluka, Sigma or Merck.




Figure 1. Synthesis of 1,4-disubstituted 1,2,3-triazole compounds from epoxides, sodium azide, and alkynes in water, catalyzed by Cu_2O under ultrasonic irradiation.

Acetylcholine and all of the synthesized compounds were dissolved in dimethyl sulfoxide (DMSO). The final concentrations of DMSO in organ bath had no effect on the tissue response.

For recorded ^1H NMR and ^{13}C NMR spectra we used Bruker (250 MHz) Avanc DRX in pure deuterated DMSO- d_6 and CDCl_3 solvents with tetramethylsilane (TMS) as internal standards. Mass spectra were recorded on a shimadzu GCMS-QP1000 EX INSTRUMENTS AT 70 or 20ev. Melting points were determined in open capillary tubes in a Barnstead Electrothermal 9100 BZ circulating oil melting point apparatus. Elemental analyses were performed on a thermo finnigan flash EA1112=1CHNS. The reaction monitoring was accomplished by thin layer chromatography (TLC) on silica gel Poly Gram SILG/UV254 plates and gas chromatography (GC).

2.1.2. Animals

Male Sprague-Dawley rats (200-220 g) were used. The animals were housed in groups of 6-7 under standard conditions (12 h light/dark cycle, temperature: 20-25 °C, and humidity: 25-35%) with standard rat chow and tap water ad libitum. All animal procedures were approved by the Institution of Animal Care and Use Committee of Shiraz University of Medical Sciences.

2.2. Methods

2.2.1. Synthesis of 1,4-disubstituted 1,2,3-triazole compounds

1,4-disubstituted 1,2,3-triazole compounds were synthesized from epoxides, sodium azide, and alkynes in water, catalyzed by Cu_2O under ultrasonic (U.S.) irradiation at room temperature (rt) (Figure 1).

For initial screening experiments, the 1,3-dipolar cycloaddition reactions between styrene oxide, sodium azide and phenylacetylene in a 1:1.1:1 molar ratio at room temperature was selected as the model reaction (Figure 2).

In the next step, we investigated the effects of using various solvents and different amounts of




Figure 2. 1,3-dipolar cycloaddition reaction between styrene oxide, sodium azide and phenylacetylene in a 1:1:1:1 molar ratio at room temperature under ultrasonic irradiation.

catalyst on the reaction time and the yields of the products (Table 1). After establishing the feasibility of the proposed method for the synthesis of the model compound, the scope of the methodology was briefly assessed by employing a set of various reactive precursors to produce 12 different 1,4-disubstituted 1,2,3-triazole compounds (Table 2).

For each reaction, epoxide (1 mmol), alkyne (1 mmol), and sodium azide (1.1 mmol) were mixed and stirred in water (2 mL) in the presence of 10 mol% of Cu_2O at room temperature in an uncapped vial under ultrasonic irradiation in temperature controlled experiments. Reactions were performed in a water bath at 25 ± 1 °C. After the completion of the reaction, as monitored by thin layer chromatography (TLC) using n-hexane/ethyl acetate, the mixture was diluted by H_2O (5 mL), it was vacuum-filtered onto a sintered-glass funnel, and the residue was consecutively washed with ethyl acetate (30 mL) and water (5 mL). The combined supernatant and organic washings were extracted with ethyl acetate (3×10 mL); the combined organic layer was dried over anhydrous

Na_2SO_4 . Removal of the solvent under vacuum, followed by purification on silica gel using hexane/ethyl acetate as the eluent, produced the pure 1,4-disubstituted-1,2,3-triazole derivatives. All the newly synthesized triazoles were characterized in detail by IR, ^1H and ^{13}C NMR, mass spectroscopy, and elemental analysis. Full analytical and spectroscopic data for all of the compounds synthesized in this study are included in the Supporting Information.

2.2.2. Assessment of vasorelaxant activity of 1,4-disubstituted 1,2,3-triazole compounds

























Animals were anesthetized with ketamine (60 mg/kg) and xylazine (8 mg/kg). The thoracic aorta was isolated and cut into four 4-mm rings. The rings were attached to hooks in an organ bath filled with bicarbonate-buffered physiological saline solutions (PSS buffer). Vascular tensions were recorded by a pressure transducer (K 30, Hugo Sachs Elektronik, Germany) using a software (HSE-ACAD, Hugo Sachs Elektronik, Germany). The PSS buffer solution was continuously


Table 1. Effects of various solvents and the catalyst concentrations on 1,3-dipolar cycloaddition reaction time and product yield.

Entry	Solvent	Catalyst (mol%)	Time [min]	Yield of product* [%]
1	#	Cu_2O (3.5 mol%)	60	0
2	Ethanol	Cu_2O (3.5 mol%)	30	70
3	water	Cu_2O (3.5 mol%)	30	95
4	DMSO	Cu_2O (3.5 mol%)	60	10
5	DMF	Cu_2O (3.5 mol%)	60	15
6	Toluene	Cu_2O (3.5 mol%)	60	5
7	Dioxane	Cu_2O (3.5 mol%)	60	10
8	Acetonitrile	Cu_2O (3.5 mol%)	60	50
9	Ethanol/water (1:1)	Cu_2O (3.5 mol%)	30	95
10	Dioxane/water (1:1)	Cu_2O (3.5 mol%)	30	80
11	water	Cu_2O (1.5 mol%)	30	65
12	water	Cu_2O (5.0 mol%)	25	95
13	water	Cu_2O (10.0 mol%)	25	98

* Isolated yields. #In the absence of solvent.

Table 2. 1,4-disubstituted 1,2,3-triazoles synthesized by reacting epoxides (1.0 mmol), terminal alkynes (1.0 mmol) and sodium azide (1.1 mmol) in the presence of Cu₂O (10 mol%) in water at room temperature under U.S. irradiation.

Entry	Alkyne	Epoxide	Product	Time [min]	Yield [%]
1	 1a	 2a	 3a	30	95
2	 1e	 2a	 3e	40	95
3	 1f	 2a	 3f	35	90
4	 1g	 2a	 3g	50	90
5	 1a	 2b	 3j	30	90
6	 1c	 2b	 3l	45	92
7	 1j	 2b	 3l	35	90
8	 1j	 2b	 3m	40	87



bubbled with O₂ (95%) and CO₂ (5%) while being refreshed every 20 minutes. The temperature was maintained at 37 °C. The aortic rings were stabilized for an hour with a resting vascular tension of 1g. After the equilibration period, cumulative concentrations of phenylephrine were added to the organ bath to reach a concentration capable of producing the maximal contraction of the aortic rings (10⁻⁷–10⁻⁶ M). After that, cumulative concentrations of triazole compounds (10⁻⁹–10⁻⁴ M) were added to the chambers while the vascular tensions of the aortic rings were recorded. Concentration-response curves were plotted and log IC₅₀ (the logarithm of the concentration that relaxes the vessel to 50% of its initial contraction), and maximal vasorelaxant effects (E_{max}) were obtained.

2.2.3. Statistical analysis

Data were presented as mean±S.E.M. and analyzed using SPSS software. One way analyses of variance (ANOVA) and post hoc Tukey's were

used. A value of p <0.05 was considered statistically significant.

3. Results

3.1. Synthesis of 1,4-disubstituted 1,2,3-triazole compounds

As shown in Table 2, we synthesized 12 different 1,4-disubstituted 1,2,3-triazole compounds using Cu (I) catalyst with high efficiency under ultrasound irradiation.

3.2. Vasorelaxant activity of 1,4-disubstituted 1,2,3-triazole compounds

The results of pharmacological evaluations are presented in Table 3. Comparison of log IC₅₀ values revealed that compounds 3f, 3g and 3l have potent vasorelaxant activity. In addition, compounds 3f and 3l showed maximal vasorelaxant response (E_{max}) even higher than Ach. Other triazoles synthesized in this study, although showing some degree of vasorelaxant activity, were un-

Table 3. Potencies and maximal efficacies of vasorelaxant 1,4-disubstituted 1,2,3-triazole compounds

Entry	Compound	Log IC ₅₀	E _{max}
1	Acetylcholine	-6.18±0.19	90.66±4.17
2	3f	-6.72±0.64	92.66±7.33
3	3g	-6.94±0.76	69.37±3.52
4	3l	-7.28±0.52	96.57±3.42

able to significantly reduce aortic tension (data not shown).

4. Discussion

In this study, we synthesized some potent vasorelaxant 1,4-disubstituted 1,2,3-triazole compounds from epoxides, sodium azide, and terminal alkynes in water, catalyzed by Cu₂O under ultrasonic irradiation. While the catalyst promoted the reaction to proceed in a regioselective manner (21), the ultrasound accelerated the reaction rate and provided easier manipulation (22, 23). Despite all the advantages of ultrasound, the number of studies that have used it to accelerate the 1,3-dipolar cycloaddition reactions is not significant. In a study by Reddy *et al.*, 1,2,3-triazole derivatives were synthesized using Cu (I) as the catalyst with the help of ultrasound waves (24). Jiang *et al.* described a method for 1,3-dipolar cycloaddition using Cu(OAc)₂/metallic copper as the catalyst under ultrasound irradiation (25). Cravatto *et al.* reported an ultrasound-assisted 1,3-dipolar cycloaddition in 1,4-dioxane/ water using metallic copper as the catalyst, at a relatively high temperature (26). It is quite certain that conducting organic reactions in water is preferred due to environmental

concerns. In comparison with other solvents, water is safe, nontoxic, economical and recyclable. In the process of optimizing the reaction conditions, we found that the best results were obtained using water as the solvent system. Therefore; our method is an example of green chemistry. Moreover, deprotonation of the π complex alkyne to form the copper acetylide can occur without the addition of a base in water, but in organic solvents, the formation of copper acetylide is unfavorable and a base is required for deprotonation (27). For the synthesis of various 1,4-disubstituted 1,2,3-triazoles, we employed various precursors and expanded the scope of the methodology. It was shown that with the help of ultrasound, various epoxides simply reacted with different terminal alkynes and sodium azide in the presence of Cu (I) to produce the desired 1,4-disubstituted 1,2,3-triazole derivatives in high yields. We were pleased that the cycloaddition reaction tolerates changes in terminal alkynes and epoxides meaning that steric and electronic variations in the reactants do not affect the reaction efficiency. Similar series of 1,4-disubstituted 1,2,3-triazole compounds have been synthesized using a supported catalyst system prepared by immobilization of a copper (II) complex of 4'-phenyl-2,2':6',2''-terpyridine on activated multi-




Figure 3. The vasorelaxant effect of 1,4-disubstituted 1,2,3-triazole compounds (10^{-9} - 10^{-4} M) on vasoconstriction induced by phenylephrine (10^{-7} - 10^{-6} M).

walled carbon nanotubes (10). In another research, 1-(2-Hydroxyethyl)-1H-1,2,3-triazole derivatives were synthesized by copper-catalyzed 1,3-dipolar cycloaddition of 2-azido alcohols and terminal alkynes (28). Compared to these methods, the method we reported in this study is much simpler and less expensive. Vasorelaxant activity of various types of triazole derivatives have been reported by some researches (29, 30). The exact mechanisms by which triazole-based compounds exert their vasorelaxant effect have not been fully elucidated, but it has been suggested that some of triazole derivatives may activate the big-conductance calcium-activated potassium channels (BK_{Ca}) (31). Other mechanisms such as angiotensin II or vasopressin I receptor antagonism also have been proposed (32). Future studies are needed to reveal the possible mechanisms of vasorelaxant activity of these compounds to design more active and selective vasorelaxant molecules.

5. Conclusion

In this work, we reported an efficient and practical procedure for the synthesis of 1,4 disubstituted 1,2,3-triazole compounds under ultrasonic waves. The potent vasorelaxant 1,4-disubstituted 1,2,3-triazole derivatives obtained in this study may serve as valuable therapeutic candidates for the design of new antihypertensive drugs.

Supporting Information

Analytical and Spectroscopic Data for Representative Compounds

2-Phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethanol (3a):

Colorless powder; 97% yield. M.p. = 126.5 °C. IR (KBr): 694(s), 760(s), 1030(m), 1049(s), 1076(s), 1118(w), 1223(m), 1427(m), 1458(s), 2928(m), 3093(m), 3398(br) cm⁻¹. ¹H NMR (CDCl₃, 250 MHz): δ = 3.62(s, 1H), 4.15(dd, *J*₁ = 12.7, *J*₂ = 3.8 Hz, 1H), 4.56(dd, *J*₁ = 12.4, *J*₂ = 8.2 Hz, 1H), 5.60(dd, *J*₁ = 8.2, *J*₂ = 3.7 Hz, 1H), 7.17-7.26(m, 5H), 7.28(s, 1H), 7.29-7.34(m, 2H), 7.62-7.69(m, 3H) ppm. ¹³C NMR (CDCl₃, 62.9 MHz): δ = 64.7, 67.3, 120.7, 126.0, 127.2, 128.2, 128.8, 129.0, 130.2, 136.2, 147.4 ppm. MS: m/z (%) = 267(0.2) [M+2]⁺, 266(2.89) [M+1]⁺, 265(6.9) [M]⁺, 218(3.7), 206(43.1), 178(9.5), 116(100.0), 77(40). C₁₆H₁₅N₃O (265.310): C 72.43, H 5.70; found C 72.56, H 5.57.

2-{4-[(1-naphthoxy)methyl]-1H-1,2,3-triazol-1-yl}-2-phenylethanol (3e):

Cream solid; 84% yield. M.p. = 89-91 °C. IR (KBr): 698(s), 765(s), 1085(s), 1256(s), 1579(s), 2854(m), 2931(m), 3398(br) cm⁻¹. ¹H NMR (CDCl₃, 250 MHz): δ = 3.56(s, 1H), 4.19(dd, *J*₁ = 12.0, *J*₂ = 3.5 Hz, 1H), 4.58(dd, *J*₁ = 12.5, *J*₂ = 7.5 Hz, 1H), 5.34(s, 2H), 5.64(dd, *J*₁ = 7.5, *J*₂ = 5.0 Hz, 1H), 6.92(d, *J* = 7.5 Hz, 1H), 7.12-7.47(m, 9H), 7.65(s, 1H), 7.78(d, *J* = 7.5 Hz, 1H), 8.25(d, *J* = 7.5 Hz, 1H) ppm. ¹³C NMR (CDCl₃, 62.9 MHz): δ = 62.3, 64.9, 67.3, 105.4, 120.9, 121.9, 125.2, 125.5, 125.7, 126.4, 127.1, 127.4, 128.9, 129.1, 134.5, 135.9, 144.2, 153.9 ppm. MS: m/z (%) = 346(5.1) [M+1]⁺, 345(8.7) [M]⁺, 225(5.1), 174(31.8), 144(100.0), 121(68.9), 81(33.8), 57(66.8). C₂₁H₁₉N₃O₂ (345.394): C 73.03, H 5.54; found C 73.11, H 5.40.

7-[[1-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-4-yl]methoxy]-4-methyl-4a,8a-dihydro-2H-chromen-2-one (3f):

Cream solid; 74% yield. M.p. = 157-158 °C. IR (KBr): 825(w), 1085(s), 1072(m), 1137(m), 1386(m), 1614(s), 1732(s), 2830(w), 3271(br) cm⁻¹. ¹H NMR ([D₆]DMSO, 250 MHz): δ = 3.40(s, 3H), 3.96-4.00(m, 1H), 4.26-4.29(m, 1H), 5.23(s, 2H), 5.32-5.35(m, 1H), 5.80(s, 1H), 6.16(s, 1H), 6.96-7.10(m, 2H), 7.60-7.64(m, 4H), 7.95-8.16(m, 1H), 8.47(s, 1H) ppm. ¹³C NMR ([D₆]DMSO, 62.9 MHz): δ = 23.2, 66.9, 68.2, 71.4, 106.7, 116.7, 117.7, 118.5, 129.7, 131.6, 132.3, 133.4, 133.8, 142.4, 146.9, 158.6, 159.8, 165.3, 166.2 ppm. MS: m/z (%) = 377(11.8) [M]⁺, 202(27.0), 174(47.6), 144(60.8), 121(100.0), 103(83.3), 54(89.8). C₂₁H₁₉N₃O₄ (377.393): C 66.83, H 5.07; found C 66.96, H 4.92.

N,N-bis[[1-(2-hydroxy-1-phenylethyl)-1H-1,2,3-triazol-4-yl]methyl]-4-methyl benzene sulfonamide (3g):

White solid; 82% yield. M.p. = 185-187 °C. IR (KBr): 698(s), 904(w), 1060(m), 1159(s), 1342(s), 1452(m), 2858(w), 3413(br) cm⁻¹. ¹H NMR ([D₆]DMSO, 250 MHz): δ = 2.24(s, 2H), 3.45(s, 3H), 3.96(m, 2H), 4.18(m, 2H), 4.45(s, 4H), 5.32(m, 2H), 5.74(m, 2H), 7.12(d, *J* = 7.5 Hz, 2H), 7.31(m, 10H), 7.53(d, *J* = 7.5 Hz, 2H), 8.47(s, 2H) ppm. ¹³C NMR ([D₆]DMSO, 62.9 MHz): δ = 26.1, 46.7, 68.3, 71.2, 128.8, 131.3, 132.1, 133.4, 133.8, 134.7, 141.5, 142.4, 146.9, 148.2 ppm. MS: m/z (%) = 574(0.4) [M]⁺, 510(2.3), 418(73.2), 298(12.3), 187(12.7), 144(20.8), 91(100.0). C₂₉H₃₁N₇O₄S (573.666): C 60.72, H 5.45; found C 60.58, H 5.36.

2-(4-Phenyl-1H-1,2,3-triazol-1-yl)cyclohexanol (3j):

Colourless solid; 91% yield. M.p. = 179-180 °C. IR (KBr): 698 (s), 771 (s), 980 (w), 1057 (s), 1088 (s), 1238 (s), 1439 (s), 2862 (w), 2943 (s), 3124 (m), 3310 (br) cm⁻¹; ¹H NMR (CDCl₃, 250 MHz): δ = 1.39-2.25 (m, 8 H), 4.09-4.17 (m, 3H), 7.23-7.36 (m, 3 H), 7.36 (dd, *J*₁ = 8.2, *J*₂ = 1.7 Hz, 2H), 7.69 (s, 1H) ppm. ¹³C NMR (CDCl₃, 62.9 MHz): δ = 24.1, 24.8, 31.5, 33.8, 67.4, 72.5, 120.1, 125.4, 127.9, 128.7, 130.2

ppm. MS: m/z (%) = 244 (2.6) $[M+1]^+$, 243 (6.7) $[M]^+$, 215 (1.5), 203 (2.6), 174 (1.7), 158 (3.7), 117 (100.0), 81 (55.7), 55 (23.5). $C_{14}H_{17}N_3O$ (243.307): C 69.11, H 7.04; found C 69.03, H 6.89.

(1R)-2-[4-(1-hydroxy-1-methylethyl)-1H-1,2,3-triazol-1-yl]cyclohexanol (3k):

White solid; 92% yield. M.p. = 144-146 °C. IR (KBr): 630(m), 964(m), 1228(m), 1639(m), 2864(m), 2943(s), 3350(br), 3562(m) cm^{-1} . 1H NMR ($CDCl_3$, 250 MHz): δ = 1.41-1.45(m, 2H), 1.60(s, 6H), 1.85-1.88(m, 4H), 2.15-2.19(m, 2H), 3.01(s, 1H), 3.71(s, 1H), 3.98-4.13(m, 2H), 7.48(s, 1H) ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 24.0, 24.8, 29.9, 31.6, 33.8, 67.0, 67.9, 72.4, 119.5, 154.4 ppm. MS: m/z (%) = 226(9.0) $[M+1]^+$, 210(7.3), 149(10.1), 111(19.9), 91(22.4), 71(36.8), 57(100.0). $C_{11}H_{19}N_3O_2$ (225.287): C 58.64, H 8.50; found C 58.51, H 8.36.

(1R)-2-(4-butyl-1H-1,2,3-triazol-1-yl)cyclohexanol (3l):

White solid; 85% yield. M.p. = 76-77 °C. IR (KBr): 962(w), 1070(s), 1218(m), 1450(s), 2858(s), 2937(s), 3258(br) cm^{-1} . 1H NMR ($CDCl_3$, 250 MHz): δ = 0.87(t, J = 7.5 Hz, 3H), 1.27-1.39(m, 6H), 1.52-1.55(m, 2H), 1.79-1.82(m, 3H), 2.06-2.11(m, 2H), 2.53-2.59(m, 2H), 3.94-4.09(m, 2H), 7.32(s, 1H) ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 13.8, 22.3, 24.0, 24.3, 25.2, 31.4, 31.7, 33.9, 66.7, 72.3, 120.5, 147.3 ppm. MS: m/z (%) = 223(1.8) $[M]^+$, 194(1.5), 99(11.2), 81(100.0). $C_{12}H_{21}N_3O$ (223.315): C 64.54, H 9.48; found C 64.45, H 9.61.

2-{4-[(4-chloro-2-nitrophenoxy)methyl]-1H-1,2,3-triazol-1-yl}cyclohexanol (3m):

Pale yellow solid; 82% yield. dc. = 145 °C. IR (KBr): 812(m), 1074(m), 1278(s), 1342(s), 1529(s), 1610(m), 2854(m), 2931(m), 3398(br) cm^{-1} . 1H NMR ($CDCl_3$, 250 MHz): δ = 1.23-2.08(m, 8H), 2.66(s, 1H), 3.99-4.01(m, 1H), 4.14-4.18(m, 1H), 5.34(s, 2H), 7.31(s, 1H), 7.25-7.35(m, 1H), 7.47-7.52(m, 1H), 7.76(s, 1H) ppm. ^{13}C NMR ($[D_6]DMSO$, 62.9 MHz): δ = 23.6, 24.3, 31.6, 34.7, 63.0, 66.0, 71.1, 117.3, 124.2, 124.4, 133.7, 133.9, 139.8, 140.9, 149.4 ppm. MS: m/z (%) = 352(13.5) $[M]^+$, 264(22.1), 236(16.0), 173(22.8), 157(25.5), 121(31.3), 97(43.6), 81(100.0), 55(92.0). $C_{15}H_{17}C_1N_4O_4$ (352.773): C 51.07, H 4.86; found C 51.18, H 4.73.

2-[4-({4-[1-(4-{[1-(3-hydroxycyclohexyl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-1-methylethyl]phenoxy}methyl)-1H-1,2,3-triazol-1-yl]cyclohexanol (3o):

White solid; 84% yield. dc. = 200 °C. IR (KBr): 906(w), 1055(m), 1161(s), 1338(s), 1456(s), 2860(m), 2935(m), 3392(br) cm^{-1} . 1H NMR ($CDCl_3$, 250 MHz): δ = 131(s,

6H), 1.42-2.12(m, 16H), 3.80(s, 2H), 3.94(m, 2H), 4.33(m, 2H), 4.90(s, 4H), 6.63(d, J = 7.5 Hz, 4H), 6.87(d, J = 7.5 Hz, 4H), 7.41(s, 2H), ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 21.5, 24.1, 24.7, 30.6, 33.5, 43.0, 67.3, 72.6, 123.8, 124.6, 127.3, 129.9, 141.7, 142.2. ppm. MS: m/z (%) = 586(0.5) $[M]^+$, 530(0.8), 465(1.8), 430(1.7), 374(100.0), 285(18.7), 195(10.3), 152(18.2), 81(49.5). $C_{33}H_{42}N_6O_4$ (586.724): C 67.55, H 7.22; found C 67.68, H 7.09.

1-Phenoxy-3-(4-phenyl-1H-1,2,3-triazol-1-yl)propan-2-ol (3p):

Colorless solid; 75% yield. M.p. = 125-126 °C. IR (KBr): 690 (s), 752 (s), 1041 (m), 1080 (m), 1119 (w), 1250 (s), 1493 (w), 1597 (m), 1724 (w), 2920 (w), 3074 (w), 3425 (b) cm^{-1} ; 1H NMR ($CDCl_3$, 250 MHz): δ = 3.88 (s, 1H), 4.01-4.05 (m, 2H), 4.55 (dd, J_1 = 12.7, J_2 = 3.5 Hz, 2H), 4.68-4.77 (m, 1H), 6.90-7.02 (m, 3H), 7.6-7.02 (m, 5H), 7.69-7.72 (m, 2H), 7.85 (s, 1H) ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 53.5, 68.6, 68.9, 114.5, 121.4, 121.6, 125.5, 128.1, 128.8, 129.6, 130.0, 147.2, 158.2 ppm. MS: m/z (%) = 297 (1.6) $[M+2]^+$, 296 (4.4) $[M+1]^+$, 295 (7.1) $[M]^+$, 279 (7.3), 243 (3.7), 222 (5.1), 202 (9.0), 167 (22.1), 149 (62.5), 117 (35.7), 94 (24.2), 77 (51.8), 57 (100.0). $C_{17}H_{17}N_3O_2$ (295.336): C 69.14, H 5.80; found C 69.03, H 5.93.

1-{4-[(1-naphthoxy)methyl]-1H-1,2,3-triazol-1-yl}-3-phenoxy-2-propanol (3q):

Brown solid; 75% yield. M.p. = 120-122 °C. IR (KBr): 792(m), 1097(s), 1240(s), 1460(s), 1598(s), 2875(m), 2931(m), 3330(br) cm^{-1} . 1H NMR ($CDCl_3$, 250 MHz): δ = 3.66(s, 1H), 3.84(m, 2H), 4.36-4.59(m, 3H), 5.23(s, 2H), 6.76-6.81(m, 4H), 7.14-7.32(m, 6H), 7.69-7.71(m, 2H), 8.12(d, J = 7.5 Hz, 1H) ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 53.0, 62.2, 68.7, 105.3, 114.4, 120.8, 121.9, 124.4, 125.3, 125.7, 126.4, 127.4, 129.6, 134.5, 144.1, 153.8, 158.0 ppm. MS: m/z (%) = 377(0.9) $[M]^+$, 280(2.3), 149(17.4), 85(40.8), 57(100.0). $C_{22}H_{23}N_3O_3$ (377.436): C 70.01, H 6.14; found C 69.88, H 6.25.

1-(Allyloxy)-3-(4-phenyl-1H-1,2,3-triazol-1-yl)propan-2-ol (3r):

Colourless solid; 87% yield. M.p. = 71.5-72 °C. IR (KBr): 698 (m), 721 (m), 860 (m), 957 (m), 1076 (s), 1165 (s), 1358 (w), 1458 (w), 2970 (m), 3128 (m), 3356 (br) cm^{-1} ; 1H NMR ($CDCl_3$, 250 MHz): δ = 3.19 (d, J = 5.0 Hz, 2H), 3.70 (d, J = 5.46 Hz, 2H), 3.96-4.11 (m, 2H), 4.27 (dd, J_1 = 13.2, J_2 = 2.6 Hz, 1H), 4.51 (s, 1H), 4.93 (dd, J_1 = 17.2, J_2 = 10.3 Hz, 1H), 4.99-5.01 (m, 1H), 5.53-5.64 (m, 1H), 6.94-7.06 (m, 3H), 7.36 (dd, J_1 = 8.2, J_2 = 1.7 Hz, 2H), 7.58 (s, 1H) ppm. ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ = 53.5, 68.9, 71.3, 72.3, 117.4, 121.0, 125.4, 128.0, 128.7, 129.7, 134.2, 147.0 ppm. MS: m/z (%) = 260 (5.4) $[M+1]^+$, 259 (10.5) $[M]^+$, 230 (4.8), 203 (11.1), 158 (14.9), 132 (16.0), 116 (100.0), 93 (4.2), 77 (46.2), 57 (37.7). $C_{14}H_{17}N_3O_2$ (295.304): C 64.85, H 6.61; found C

64.97, H 6.49.

Acknowledgment

We acknowledge Shiraz University for

partial support of this work.

Conflict of Interest

The authors declare no conflict of interest.

References

- Alraqa SY, Alharbi K, Aljuhani A, Rezki, Aouad NMR, Ali I. Design, click conventional and microwave syntheses, DNA binding, docking and anticancer studies of benzotriazole-1,2,3-triazole molecular hybrids with different pharmacophores. *J Mol Struct.* 2021. 1225: p. 129192.
- Alam MM. 1,2,3-Triazole hybrids as anticancer agents: A review. *Arch Pharm (Weinheim).* 2022 Jan;355(1):e2100158. doi: 10.1002/ardp.202100158. Epub 2021 Sep 24. PMID: 34559414.
- Sharma A, Agrahari AK, Rajkhowa S, Tiwari VK. Emerging impact of triazoles as anti-tubercular agent. *Eur J Med Chem.* 2022 Aug 5;238:114454. doi: 10.1016/j.ejmech.2022.114454. Epub 2022 May 13. PMID: 35597009.
- Bozorov K, Zhao J, Aisa HA. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. *Bioorg Med Chem.* 2019 Aug 15;27(16):3511-3531. doi: 10.1016/j.bmc.2019.07.005. Epub 2019 Jul 4. PMID: 31300317; PMCID: PMC7185471.
- Chauhan S, Verma V, Kumar D, Kumar A. Synthesis, antimicrobial evaluation and docking study of triazole containing triaryl-1H-imidazole. *Synth Commun.* 2019. 49(11): p. 1427-1435.
- Phatak PS, Sathe BP, Dhumal ST, Rehman A, Dixit PP, Khedkar VM, Haval KP. Synthesis, Antimicrobial Evaluation, and Docking Studies of Substituted Acetylphenoxymethyl-triazolyl-N-phenylacetamides. *J Heterocyclic Chem.* 2019. 56(7): p. 1928-1938.
- Viegas DJ, da Silva VD, Buarque CD, Bloom DC, Abreu PA. Antiviral activity of 1,4-disubstituted-1,2,3-triazoles against HSV-1 in vitro. *Antivir Ther.* 2020;25(8):399-410. doi: 10.3851/IMP3387. PMID: 33705354.
- Azim T, Wasim M, Akhtar MS, Akram I. An in vivo evaluation of anti-inflammatory, analgesic and anti-pyretic activities of newly synthesized 1, 2, 4 Triazole derivatives. *BMC Complement Med Ther.* 2021 Dec 31;21(1):304. doi: 10.1186/s12906-021-03485-x. PMID: 34972515; PMCID: PMC8720215.

- Feng LS, Zheng MJ, Zhao F, Liu D. 1,2,3-Triazolehybrids with anti-HIV-1 activity. *Arch Pharm (Weinheim).* 2021 Jan;354(1):e2000163. doi: 10.1002/ardp.202000163. Epub 2020 Sep 22. PMID: 32960467.
- Sharghi H, Ebrahimpourmoghaddam S, Doroodmand MM, Purkhosrow A. Synthesis of Vasorelaxing 1,4-Disubstituted 1,2,3-Triazoles Catalyzed by a 4'-Phenyl-2,2':6',2''-Terpyridine Copper(II) Complex Immobilized on Activated Multiwalled Carbon Nanotubes. *Asian J Org Chem.* 2012. 1(4): p. 377-388.
- Salma U, Ahmad S, Alam MDZ, Khan SA. A review: Synthetic approaches and biological applications of triazole derivatives. *J Mol Struct.* 2024. 1301: p. 137240.
- Aflak N, Ben El Ayouchia H, Bahsis L, Anane H, Julve M, Stiriba SE. Recent Advances in Copper-Based Solid Heterogeneous Catalysts for Azide-Alkyne Cycloaddition Reactions. *Int J Mol Sci.* 2022 Feb 21;23(4):2383. doi: 10.3390/ijms23042383. PMID: 35216495; PMCID: PMC8874673.
- Aflak N, Ben El Ayouchia H, Bahsis L, El Mouchtari EM, Julve M, Rafqah S, et al. Sustainable Construction of Heterocyclic 1,2,3-Triazoles by Strict Click [3+2] Cycloaddition Reactions Between Azides and Alkynes on Copper/Carbon in Water. *Front Chem.* 2019 Feb 19;7:81. doi: 10.3389/fchem.2019.00081. PMID: 30838201; PMCID: PMC6389623.
- Lamarque J-F, Lamarque C, Lassara S, Médebielle M, Molette J, David E. Copper catalyzed 1,3-dipolar cycloaddition reaction of azides with N-(2-trifluoroacetylaryl)propargylamines: A mild entry to novel 1,4-disubstituted-[1,2,3]-triazole derivatives. *J Fluor Chem.* 2008. 129(9): p. 788-798.
- Hein JE, Fokin VV. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. *Chem Soc Rev.* 2010 Apr;39(4):1302-15. doi: 10.1039/b904091a. Epub 2010 Mar 4. PMID: 20309487; PMCID: PMC3073167.
- Jiang Y, Kong D, Zhao J, Zhang W, Xu W, Li W, Xu G. A simple, efficient thermally promot-

ed protocol for Huisgen-click reaction catalyzed by CuSO₄·5H₂O in water. *Tetrahedron Letters*, 2014. 55(15): p. 2410-2414.

17. Majhi S. Applications of ultrasound in total synthesis of bioactive natural products: A promising green tool. *Ultrason Sonochem*. 2021 Sep;77:105665. doi: 10.1016/j.ultsonch.2021.105665. Epub 2021 Jul 18. PMID: 34298310; PMCID: PMC8322467.

18. Machado IV, Dos Santos JRN, Januario MAP, Corrêa AG. Greener organic synthetic methods: Sonochemistry and heterogeneous catalysis promoted multicomponent reactions. *Ultrason Sonochem*. 2021 Oct;78:105704. doi: 10.1016/j.ultsonch.2021.105704. Epub 2021 Aug 5. PMID: 34454180; PMCID: PMC8406036.

19. Gibault F, Sturbaut M, Coevoet M, Pugnière M, Burtcher A, Allemand F, Melnyk P, Hong W, Rubin BP, Pobbati AV, Guichou JF, Cotellet P, Bailly F. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex. *ChemMedChem*. 2021 Sep 16;16(18):2823-2844. doi: 10.1002/cmdc.202100153. Epub 2021 Jul 1. PMID: 34032019.

20. Babic-Samardzija K, Hackerman N. Triazole, benzotriazole and substituted benzotriazoles as corrosion inhibitors of iron in aerated acidic media. *J Solid State Electrochem*. 2005. 9: p. 483-497.

21. Vala DP, Vala RM, Patel HM. Versatile Synthetic Platform for 1,2,3-Triazole Chemistry. *ACS Omega*. 2022 Oct 10;7(42):36945-36987. doi: 10.1021/acsomega.2c04883. PMID: 36312377; PMCID: PMC9608397.

22. Kiranmye T, Vadivelu M, Sampath S, Muthu K, Karthikeyan K. Ultrasound-assisted catalyst free synthesis of 1,4-/1,5-disubstituted-1,2,3-triazoles in aqueous medium. *Sustain Chem Pharm*. 2021. 19: p. 100358.

23. Rezki N, Aouad MR. Green ultrasound-assisted three-component click synthesis of novel 1H-1,2,3-triazole carrying benzothiazoles and fluorinated-1,2,4-triazole conjugates and their antimicrobial evaluation. *Acta Pharm*. 2017 Sep

1;67(3):309-324. doi: 10.1515/acph-2017-0024. PMID: 28858836.

24. Sreedhar B, Surendra ReddP, Sonochemical Synthesis of 1,4-Disubstituted 1,2,3-Triazoles in Aqueous Medium. *Syn Communi*. 2007. 37(5): p. 805-812.

25. Jiang Y, Chen X, Qu L, Wang J, Yuan J, Chen S, Li X. An Efficient Ultrasound-assisted Method for the Synthesis of 1,4-Disubstituted Triazoles. *Z Naturforsch B*. 2011;66(1): 77-82.

26. Cintas P, Barge A, Tagliapietra S, Boffa L, Cravotto G. Alkyne-azide click reaction catalyzed by metallic copper under ultrasound. *Nat Protoc*. 2010 Mar;5(3):607-16. doi: 10.1038/nprot.2010.1. Epub 2010 Mar 4. PMID: 20203675.

27. Shilpa T, Neetha M, Anilkumar G. Recent Trends and Prospects in the Copper-Catalysed "on Water" Reactions. *Adv Synth Catal*. 2021. 363(6): p. 1559-1582.

28. Sharghi H, Hosseini-Sarvari M, Moeini F, Khalifeh R, Beni A. One-Pot, Three-Component Synthesis of 1-(2-Hydroxyethyl)-1H-1,2,3-triazole Derivatives by Copper-Catalyzed 1,3-Dipolar Cycloaddition of 2-Azido Alcohols and Terminal Alkynes under Mild Conditions in Water. *Helvetica Chimica Acta*, 2010. 93(3): p. 435-449.

29. Kumar S, Khokra SL, Yadav A. Triazole analogues as potential pharmacological agents: a brief review. *Futur J Pharm Sci*. 2021;7(1):106. doi: 10.1186/s43094-021-00241-3. Epub 2021 May 25. PMID: 34056014; PMCID: PMC8148872.

30. Kharb R, Sharma PC, Yar MS. Pharmacological significance of triazole scaffold. *J Enzyme Inhib Med Chem*. 2011 Feb;26(1):1-21. doi: 10.3109/14756360903524304. Epub 2010 Jun 28. PMID: 20583859.

32. Kakefuda A, Suzuki T, Tobe T, Tsukada J, Tahara A, Sakamoto S, et al. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. *J Med Chem*. 2002 Jun 6;45(12):2589-98. doi: 10.1021/jm010544r. PMID: 12036368.